GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Cullinan Therapeutics CGEM · USD

Health Care · US listing · 🇺🇸 United States

Compare

11.73

+3.71%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Cullinan Therapeutics

From its filings with the US Securities and Exchange Commission

SEC filings

Cullinan Therapeutics is based in Cambridge, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker CGEM. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2022, it reported revenue of $0.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
8 Jan 2021
Employees
109
Head office
ONE MAIN STREET, CAMBRIDGE, MA, 02142
Incorporated in
DE
Classification
Biological Products, (No Diagnostic Substances)
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Mr. Anthony RosenbergIndependent Chairman of the Board$258,413
  • Mr. Nadim AhmedPresident, Chief Executive Officer, Director, since 2021$7.7m
  • Ms. Mary FentonChief Financial Officer, Principal Financial Officer, Principal Accounting Officer$4.1m
  • Dr. Jennifer MichaelsonChief Scientific Officer
  • Ms. Jacquelyn SumerChief Legal and Compliance Officer, Company Secretary
  • Dr. Jeffrey JonesChief Medical Officer$3.4m
  • Ms. Corinne SavillChief Business Officer$486,200
  • Dr. Andrew AllenDirector
  • Dr. Mittie DoyleDirector
  • Mr. David MeekIndependent Director$304,476
  • Ms. Mary ThistleIndependent Director$292,546
  • Mr. Stephen WebsterIndependent Director$229,864

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
46
Environment
51
Social
41
Governance
46
Carbon reduction policy
No
Human rights policy
No

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Cullinan Therapeutics Inc employs 109 employees in Cambridge, Massachusetts.
  • Cullinan Oncology, Inc. focuses on developing oncology therapies for cancer patients.
  • Zipalertinib (CLN-081/TAS6417) is in Phase IIb for NSCLC with EGFRex20ins mutations.

Weaknesses

  • Cullinan Therapeutics Inc has 62 full-time employees as of the IPO date.
  • The company's lead candidate is in Phase IIb clinical trials for NSCLC.
  • Cullinan's product pipeline includes CLN-049 for AML and MDS.

Opportunities

  • Cullinan Therapeutics Inc is developing CLN-049 for relapsed/refractory AML and MDS.
  • The company's focus on EGFRex20ins mutations offers a targeted therapy opportunity.
  • Cullinan's Phase IIb trial for Zipalertinib could expand treatment options.

Threats

  • Cullinan Therapeutics Inc faces competition in the biopharmaceutical sector.
  • The company's clinical trials may encounter delays or failures.
  • Cullinan's product candidates require significant regulatory approvals.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.